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AFFORD study: n-3 Polyunsaturated Fatty Acids (Fish 
Oil) do not Reduce Atrial Fibrillation Recurrences  
In a double-blind, randomized, placebo-controlled trial 
of fish oil (4 g/day, docosahexaenoic acid - DHA: 
eicosapentaenoic acid - EPA 1:2) vs safflower oil placebo 
in 337 patients with symptomatic paroxysmal or persistent 
AF followed for 9 ± 4 months, the primary endpoint (time 
to first symptomatic or asymptomatic AF recurrence 
lasting >30 s) occurred in 64% of patients in the fish oil 
arm and 63% of patients in the placebo arm (hazard ratio: 
1.10; p= NS). hs-CRP and myeloperoxidase - MPO were 
normal at baseline and decreased to a similar degree at 6 
months. The authors concluded that high-dose fish oil does 
not reduce AF recurrence in patients with a history of AF 
not receiving AA therapy, and does not reduce 
inflammation or oxidative stress markers in this population 
(Nigam A et al, J Am Coll Cardiol 2014;64:1441-1448).  
N.B.: Another randomized study (VITAL - VITamin D 
and OmegA-3 TriaL) is currently examining the effect of 
1 g/d of n-3 PUFAs on AF in a much larger population 
(N=25,875) without cardiac disease over 5 years.  
 
RELAX-AHF: Serelaxin Reduces Mainly Cardiova-
scular & Sudden Deaths, Rather than HF Deaths 
The RELAX-AHF study showed that IV serelaxin 
(recombinant human relaxin-2) compared with placebo 
reduced mortality at 6 months among 1,161 patients with 
acute heart failure (HF). In this group there were 107 
deaths (9.3%): 37 (35%) from HF, 25 (23%) from sudden 
death, 15 (14%) from other cardiovascular (CV) causes, 19 
(18%) from non-CV causes, and 11 (10%) classified as 
unknown. The treatment effect of serelaxin was most 
pronounced on other CV deaths (hazard ratio - HR: 0.29; 
p= 0.005) and sudden death (HR: 0.46; p= 0.065), with no 
effect of serelaxin treatment on HF or non-CV deaths. The 
authors concluded that the effects of serelaxin on mortality 
were mainly due to reduced CV causes and sudden death, 
without apparent effect on HF deaths (Feleker GM et al, J 
Am Coll Cardiol 2014;64:1591-1598). N.B.: an ongoing 
large phase III outcome trial (NCT01870778) will further 
examine serelaxin’s effect on mortality. 
 
ARISTOTLE: Anticoagulation Quality was Lower in 
Warfarin-Treated Patients who Received Amiodarone, 
and Amiodarone was Associated with Significantly 
Higher Risk of Thrombo-embolism, while Apixaban 
had a Benefit over Warfarin in Both Groups 
In the ARISTOTLE trial, 2,051 (11.4%) patients 
received amiodarone. Time in the therapeutic range (TTR) 
in patients on warfarin and amiodarone was lower than 
patients not on amiodarone (56.5% vs 63%; p<0.0001). 
More patients on amiodarone had thromboembolism 
(stroke or systemic embolism) (1.58%/year vs 1.19%/year; 
hazard ratio -HR: 1.47; p= 0.0322). Mortality and major 
bleeding rates were higher, albeit not significantly 
different, in the amiodarone vs the non-amiodarone group. 
Apixaban, compared with warfarin, decreased systemic 
embolism, death, and major bleeding in both groups. The 
authors concluded that amiodarone was associated with 
significantly increased stroke and systemic embolism risk 
and a lower TTR when used with warfarin. Apixaban 
consistently reduced the rate of stroke and systemic 
embolism, death, and major bleeding compared with 
warfarin in both (amiodarone and non-amiodarone) groups 
(Flaker G et al, J Am Coll Cardiol 2014;64:1541-1550).  
 
Catheter-Based Transapical Mitral Valve Implanta-
tion was Successful in First 2 Cases with Severe 
Ischemic Cardiomyopathy and Mitral Regurgitation  
The first-in-man 2 cases of transapical mitral valve 
implantation with the Tiara device was successfully 
performed in a 73-year-old man and a 61-year-old woman 
with severe functional mitral regurgitation (MR) and heart 
failure with no need for cardiopulmonary bypass. Systemic 
arterial pressure and stroke volume increased and 
pulmonary pressure decreased, immediately after the 
procedure. Both patients were extubated in the operating 
room and had an uncomplicated course. Echocardiograms 
at 48 h, 1 and 2 months demonstrated excellent prosthetic 
valve function. There was a small paravalvular leak in the 
first patient at 48 h, which was completely resolved at 
subsequent studies. The authors concluded that transapical 
transcatheter mitral valve implantation is technically 
feasible and can be performed safely (Cheung A et al, J 
Am Coll Cardiol 2014;64:1814-1819).  
 
SECURITY Trial: In a Low-Risk Population, 6-Month 
Dual Antiplatelet Therapy After Second-Generation 
Drug Eluting Stent Implantation Appears Acceptable  
In the SECURITY trial, 1,399 patients were randomi-
zed to receive 6 (n=682) vs 12 months (n=717) dual 
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antiplatelet therapy (DAPT). The primary endpoint 
(composite of cardiac death, myocardial infarction -MI, 
stroke, definite or probable stent thrombosis, or Bleeding 
Academic Research Consortium -BARC type 3 or 5 
bleeding at 12 months) was not different in the 2 groups. 
No differences were observed in the occurrence of the 
secondary endpoint (composite of cardiac death, MI, 
stroke, definite or probable stent thrombosis, or BARC 
type 2, 3, or 5 bleeding at 12 and 24 months). Finally, no 
differences were observed in definite or probable stent 
thrombosis at 12 months (0.3% vs 0.4%) and between 12 
and 24 months of follow-up (0.1% vs 0%). The authors 
concluded that in a low-risk population, the noninferiority 
hypothesis of 6 vs. 12 months DAPT following second-
generation DES implantation appears acceptable 
(Colombo A et al, J Am Coll Cardiol 2014;64:2086-2097).  
 
MESA Study: Positive Associations Between Baseline-
Corrected QT Intervals and Risks of Stroke, Heart 
Failure, and Cardiovascular Disease (CVD) Events in 
Middle-Aged Individuals Free of CVD at Baseline  
The corrected baseline 12-lead ECG QT interval 
duration (QTc) was determined in 6,273 participants 
(mean age 62 ± 10 years; 53% women) in MESA (Multi-
Ethnic Study of Atherosclerosis). Cardiovascular events 
occurred in 291 participants over a mean follow-up of 8 ± 
1.7 years. Each 10-ms increase in the baseline QTc was 
associated with incident heart failure (hazard ratio -HR: 
1.25), CVD events (HR: 1.12), and stroke (HR: 1.19). 
There was no evidence of interaction with gender or 
ethnicity. The authors concluded that the QT interval was 
associated with incident cardiovascular events in middle-
aged and older adults without prior CVD (Beinart R et al, 
J Am Coll Cardiol 2014;64:2111-2119).  
 
ARREST-AF Study: Aggressive Risk Factor Reduction 
Improved Outcomes of AF Ablation by Reducing AF 
Burden and Severity Together With Favorable 
Changes in Cardiac Remodeling  
Risk factor management (RFM) was offered to 149 of 
281 consecutive patients undergoing AF ablation who had 
a body mass index ≥27 kg/m2 and ≥1 cardiac risk factor. 
After AF ablation, RFM applied in 61 patients resulted in 
greater reductions in weight (p= 0.002) and blood pressure 
(p= 0.006), and better glycemic control (p= 0.001) and 
lipid profiles (p= 0.01). At follow-up, AF frequency, 
duration, symptoms, and symptom severity decreased 
more in the RFM group compared with the control group 
(n=88) (all p< 0.001). Post-procedural arrhythmia-free 
survival was greater in RFM patients either with single or 
multiple procedures (p< 0.001). On multivariate analysis, 
type of AF (p< 0.001) and RFM (hazard ratio 4.8; p< 
0.001) were independent predictors of arrhythmia-free 
survival. The authors concluded that aggressive RFM 
improved the long-term success of AF ablation (Pathak RK 
et al, J Am Coll Cardiol 2014;64:2222-2231).  
 
FOCUS Project: Polypill Strategy Improves 
Adherence 
Among 2,118 post-MI patients, in phase 1 of the 
FOCUS (Fixed-Dose Combination Drug for Secondary 
Cardiovascular Prevention) study, overall cardiovascular 
(CV) medication adherence, was 45.5%. In a multivariate 
analysis, the risk of being nonadherent was associated with 
younger age, depression, receiving complex medication 
regimen, poorer health insurance coverage, and a lower 
level of social support. In phase 2, 695 patients were 
randomized to a polypill (aspirin 100 mg, simvastatin 40 
mg, and ramipril 2.5, 5, or 10 mg) vs 3 drugs given 
separately. Over 9 months, the polypill group showed 
improved adherence: 51% vs 41% (p=0.019; intention-to-
treat)/ ~66% vs 56% (p=0.012; per protocol). The authors 
concluded that for secondary prevention following acute 
MI, younger age, depression, and a complex drug regimen 
are associated with lower medication adherence, while a 
polypill strategy increased adherence (Castellano JM et al, 
J Am Coll Cardiol 2014;64:2071-2082).  
 
Cardiac Deaths After Primary PCI Cluster in the First 
Month, While Later NonCardiac Deaths Prevail and 
Annual Cardiac Mortality Declines to <1.5% 
Among 2,804 consecutive patients with STEMI (age 63 
± 13 y, 72% males) treated with primary PCI and followed 
up for a median of 4.7 years, 717 patients died. Main 
causes of death within the first month were cardiogenic 
shock and anoxic brain injury after cardiac arrest. Age, 
culprit vessel size and flow, heart failure and diabetes were 
independent predictors of mortality. After the first month, 
noncardiac causes of death prevailed (65%; mainly 
malignancies and pulmonary diseases), while the annual 
cardiac mortality rate declined to <1.5%. 1-month, 1-year, 
and 5-year all-cause (and cardiac) mortality rates were 
~8%, 11%, & 23%, respectively. The authors concluded 
that patients who survive the first month after STEMI 
treated with primary PCI have an excellent prognosis, with 
a<1.5% annual cardiac mortality risk, while noncardiac 
causes are responsible for the majority of later deaths 
(Pedersen F et al, J Am Coll Cardiol 2014;64:2101-2108).  
 
Multicenter Evaluation of a Third-Generation Balloon-
Expandable Transcatheter Aortic Valve: New Valve 
Addresses Deficiencies of Earlier Transcatheter Valves  
The SAPIEN 3 (Edwards Lifesciences Inc., Irvine, 
California) transcatheter valve claims a low-profile 
delivery system that facilitates implantation and an 
external seal that minimizes paravalvular regurgitation. 
The valve was evaluated in a prospective study of 150 
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patients at 16 sites in Europe and Canada (aged 83.6 ± 5.0 
years; TCT score 7.4 ± 4.5% and logistic EuroSCORE 21.6 
± 12.3%; transfemoral approach in 64.0%). At 30 days, 
paravalvular regurgitation was 0 to mild in ~96%. 
Transfemoral approach had low mortality (2.1%), no 
disabling stroke (0.0%), and fully percutaneous access and 
closure in 96%. Nontransfemoral access was associated 
with higher rates of mortality (11.6%) and stroke (5.6%). 
The authors concluded that the new valve addresses major 
deficiencies of earlier valves in terms of ease of use, 
accuracy of positioning, and paravalvular sealing, with low 
rates of mortality and stroke via transfemoral access. 
(Webb J et al, J Am Coll Cardiol 2014;64:2235-2243).  
 
ACCOAST-PCI Study: In Patients with NSTEMI, the 
Data Support Deferring a Loading Dose of Prasugrel 
until a Decision is Made About PCI  
Among 4,033 patients with NSTEMI, 68.7% 
underwent PCI; 1,394 received pre-treatment with 
prasugrel (30-mg loading dose), and 1,376 received 
placebo. At the time of PCI, patients who received pre-
treatment with prasugrel received an additional 30-mg 
dose of prasugrel, and those who received placebo 
received a 60-mg loading dose of prasugrel. The incidence 
of the primary endpoint (composite of cardiovascular 
death, MI, stroke, urgent revascularization, or glycoprotein 
IIb/IIIa bailout) at 7 days in the pre-treatment group vs the 
no pre-treatment group was similar (13.1% vs 13.1%). 
Patients with thrombus on angiography had a 3-fold higher 
incidence of the primary endpoint than patients without 
thrombus. There was no impact of pre-treatment with 
prasugrel on the presence of thrombus before PCI or on 
occurrence of stent thrombosis after PCI. There was a 3-
fold increase in major bleeding and a 6-fold increase in 
life-threatening bleeding with pre-treatment with 
prasugrel; same trends persisted in patients who had radial 
or femoral access even with use of a closure device. The 
authors concluded that these data support deferring 
treatment with prasugrel until a decision is made about 
revascularization in patients with NSTEMI undergoing 
angiography within 48 h of admission (Montalescot G et 
al, J Am Coll Cardiol 2014;64:2563-2571).  
 
TRA 2°P-TIMI 50 Trial: Vorapaxar, a Novel 
Antiplatelet Agent Inhibiting Platelet Protease-
Activated Receptor (PAR)-1, Reduced Risk of Definite 
Stent Thrombosis Consistently Over Time not 
Modified by Background Use of DAPT  
 TRA 2°P-TIMI 50 (Trial to Assess the Effects of 
Vorapaxar in Preventing Heart Attack and Stroke in 
Patients With Atherosclerosis-Thrombolysis In 
Myocardial Infarction 50) randomized 26,449 patients, 
with 14,042 (53%) having a history of a coronary stent 
implantation before randomization, and 449 patients 
receiving a coronary stent during the trial (total 14,491). 
During a median 2.5 years, there were 152 definite stent 
thrombosis (ST) events (majority - 92% occurring late). 
Vorapaxar reduced definite ST (1.1% vs 1.4%, hazard ratio 
- HR: 0.71; p= 0.037) consistently over time after PCI, not 
modified by diabetes, use of drug-eluting stents, or use of 
dual antiplatelet therapy (DAPT). Vorapaxar increased 
moderate/severe bleeding (HR: 1.57; p< 0.001). The 
authors concluded that vorapaxar reduced definite ST 
(~1.4% at 3 years) in stable patients with coronary stenting 
receiving standard antiplatelet therapy (Bonaca MP et al, J 
Am Coll Cardiol 2014;64:2309-2317).  
 
PARTNER Trial: TAVI Confers Better Survival and 
Functional Status in Inoperable Patients with Severe 
Aortic Stenosis with Durable Benefit Over 3 Years, 
Albeit with High Residual Mortality  
In the Placement of Aortic Transcatheter Valves 
(PARTNER) study, among the 358 patients randomly 
assigned to transcatheter aortic valve implantation (TAVI) 
or standard therapy and all randomly assigned inoperable 
patients (n=449), including the randomized portion of the 
continued access study (n=91), the 3-year mortality rate in 
TAVI patients was 54.1% and 80.9% in the standard 
therapy group (P<0.001; hazard ratio-HR, 0.53; P<0.001). 
In survivors, there was significant improvement in NYHA 
functional class sustained at 3 years. The cumulative 
incidence of strokes at 3-year follow-up was 15.7% in 
TAVI patients vs 5.5% in patients with standard therapy 
(HR, 2.81; P=0.012); however, the composite of death or 
strokes was significantly lower after TAVI vs standard 
therapy (57.4% vs 80.9%, P<0.001; HR, 0.60; P<0.001). 
The authors concluded that TAVI resulted in better 
survival and functional status in inoperable patients with 
severe aortic stenosis with durable hemodynamic benefit 
on long-term follow-up. However, there is high residual 
mortality even in successfully treated TAVI patients 
(Kapadia SR et al, Circulation 2014; 130: 1483-1492).  
 
A 5-Year United States PCI Experience (2005–2009): 
Significant Impact of Annual Operator and 
Institutional Volume on PCI Outcomes 
 According with a Nationwide 5-year sample (2005-
2009) of 457 498 percutaneous coronary interventions 
(PCIs) out of a total of 2 243 209 PCIs performed in the 
United States, in-hospital, all-cause mortality was 1.08%, 
and the overall complication rate was 7.10%. The primary 
(in-hospital mortality) and secondary outcomes (in-
hospital mortality and peri-procedural complications) of 
procedures performed by operators in 4th (>100 annual 
procedures), 3rd (45–100 procedures), and 2nd quartile (16–
44 procedures) were significantly less (P<0.001) when 
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compared with those by operators in the 1st quartile (≤15 
procedures). Similarly operators in the higher quartiles 
witnessed a significant reduction in length of hospital stay 
and cost (P<0.001). The authors concluded that overall in-
hospital mortality after PCI was low. An increase in 
operator and institutional volume of PCI was found to be 
associated with a decrease in adverse outcomes, length of 
hospital stay, and cost of hospitalization (Badheka AO et 
al, Circulation 2014; 130: 1392-1406).  
 
ARIC Study: Most Patients With Incident Heart 
Failure (HF) Have Pre-Existing Overweight or Obesity 
and Once they Develop HF, they Have Lower Mortality 
Compared With Those With Prior Normal BMI / A 
Significant Component of this Obesity Paradox is 
Driven by Pre-Morbid Obesity 
In the ARIC (Atherosclerosis Risk In Communities) 
study, among 1,487 patients with incident heart failure 
(HF), 35% were overweight and 47% were obese before 
HF diagnosis. Over 10-year follow-up after incident HF, 
43% of patients died. Being pre-morbidly overweight 
(hazard ratio -HR: 0.72; p= 0.004) or obese (HR: 0.70; p= 
0.001) had a protective association with survival compared 
with normal BMI. The authors concluded that patients who 
were overweight or obese before HF development have 
lower mortality after HF diagnosis compared with patients 
with normal body mass index (BMI) (Khalid U et al, J Am 
Coll Cardiol 2014;64:2743-2749). 
 
RADAR-AF Trial: In Paroxysmal AF, Localized High-
Frequency Source Ablation (HFSA) was Inferior at 6 
Months but was as Efficacious as Circumferential 
Pulmonary Vein Isolation (CPVI) at 1 Year, While in 
Persistent AF, CPVI+ HFSA Offered no Incremental 
Value, With a Trend to More Complications  
Among 232 patients (age 53±10 y), those with 
paroxysmal AF (n=115) were randomized to 
circumferential pulmonary vein isolation (CPVI) or 
localized high-frequency source ablation (HFSA)-only and 
those with persistent AF (n=117) to CPVI or a combined 
ablation approach (CPVI+HFSA). In paroxysmal AF, 
HFSA failed to achieve noninferiority at 6 months after a 
single procedure but, after redo procedures, was 
noninferior to CPVI at 12 months for freedom from AF 
with fewer serious adverse events. In persistent AF, there 
were no significant differences between treatment groups 
for AF recurrences, but CPVI+HFSA trended toward more 
serious adverse events (Atienza F et al, J Am Coll Cardiol 
2014;64:2455-2467).  
 
Improved Survival After Out-of-Hospital Cardiac 
Arrest and Use of Automated External Defibrillators 
According with a population-based cohort study of out-
of-hospital cardiac arrest (2006-2012), use of automated 
external defibrillators (AED) led to an increase in the rates 
of survival with favorable neurologic outcome (N=6133, 
16.2% to 19.7%; P for trend=0.021), albeit only in patients 
presenting with a shockable initial rhythm (N=2823; 
29.1% to 41.4%; P for trend<0.001). Rates of AED use 
almost tripled during the study period (21.4% to 59.3%; P 
for trend <0.001), The authors concluded that increased 
AED use is associated with increased survival in patients 
with a shockable initial rhythm, recommending continuous 
efforts to introduce or extend AED programs (Blom MT et 
al, Circulation 2014; 130: 1868-1875).  
 
Tetralogy of Fallot: Low Late Mortality at Prospective 
Follow-Up of 40 Years After Surgical Correction 
According to a longitudinal cohort study of 136 out of 
144 patients with tetralogy of Fallot who underwent 
surgical repair at <15 years of age (1968-1980), 
cumulative survival was 72% after 40 years. Late mortality 
was due to heart failure and ventricular fibrillation. For 72 
of 80 survivors participating in further in-hospital 
investigation, cumulative event-free survival was 25% 
after 40 years. Although systolic right and left ventricular 
function declined, peak exercise capacity remained stable. 
A previous shunt operation (hazard ratio-HR, 2.9), low 
temperature during surgery (HR 1.1), and early 
postoperative arrhythmias (HR 2.5) were found to predict 
late mortality. An increase in QRS duration and worsening 
exercise tolerance and ventricular dysfunction did not 
predict mortality. Insertion of a transannular patch was a 
predictor for late arrhythmias (HR, 4.0) (Cuypers J et al, 
Circulation 2014; 130: 1944-1953).  
 
MADIT-CRT Trial: Left Ventricular Ejection 
Fraction Normalization in Cardiac Resynchronization 
Therapy (CRT) Decreases Risk of Ventricular 
Arrhythmias and Improves Clinical Outcomes  
Among 752 patients in the MADIT-CRT trial a total of 
7.3% achieved left ventricular ejection fraction (LVEF) 
normalization (>50%) over 2.2±0.8 years. The risk of 
ventricular tachyarrhythmias (VTA) was reduced in 
patients with LVEF >50% (hazard ratio -HR, 0.24; 
P=0.023) and LVEF of 36-50% (HR, 0.44; P<0.001). 
Among patients with LVEF >50%, only 1 patient had VTA 
≥200 bpm (HR, 0.16), none were shocked by the ICD, and 
2 died of nonarrhythmic causes. The risk of HF or death 
was reduced with improvements in LVEF. A total of 6 
factors were associated with LVEF normalization, and 
patients with all factors present (n=42) did not experience 
VTAs. The authors concluded that patients who achieve 
LVEF normalization (>50%) have very low absolute and 
relative risk of VTAs and a favorable clinical course within 
2.2 years of follow-up. They recommend that these 
patients could be considered for downgrade from CRT-
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defibrillator to CRT-pacemaker at time of battery 
replacement if no VTAs have occurred (Ruwald MH et al, 
Circulation 2014; 130: 2278-2286).  
 
X-VeRT: Oral Rivaroxaban an Effective & Safe Alter-
native to VKA/May Allow Prompter Cardioversion 
 Among 1504 patients with AF scheduled for 
cardioversion, the primary efficacy outcome (stroke, TIA, 
peripheral embolism, MI, and cardiovascular death) 
occurred in 5 (2 strokes) of 978 patients (0.51%) assigned 
to rivaroxaban and in 5 (2 strokes) of 492 patients (1.02%) 
receiving VKA (risk ratio – RR 0.50). In the rivaroxaban 
group, 4 (0.71%) patients experienced primary efficacy 
events following early (at 1-5 days) & 1 (0.24%) following 
delayed (3-8 weeks) cardioversion. In the VKA group, 3 
(1.08%) had primary efficacy events following early and 2 
(0.93%) following delayed cardioversion. Rivaroxaban 
was associated with a significantly shorter time to 
cardioversion compared with VKAs (P<0.001). Major 
bleeding occurred in 6 (0.6%) in the rivaroxaban group and 
4 patients (0.8%) in the VKA group (RR 0.76). The authors 
concluded that rivaroxaban is an effective and safe 
alternative to VKAs and may allow prompt cardioversion 
(Cappato R et al, Eur Heart J 2014; 35: 3346-3355).  
 
AMIO-CAT trial: Short-Term Oral Amiodarone 
Treatment Following Ablation for Paroxysmal or 
Persistent AF did not Significantly Reduce AF 
Recurrence at 6-Months, but Prolonged Time to First 
Recurrence and Reduced Arrhythmia-Related 
Hospitalization and Cardioversion Rates  
A total of 212 patients (median age 61 years) 
undergoing AF ablation were randomly assigned to 8 
weeks of oral amiodarone or placebo post-procedurally. 
Recurrence was observed in 42/107 (39%) in the 
amiodarone group vs 48/99 (48%) in the placebo group (P 
= NS). The amiodarone group had significantly lower rate 
of arrhythmia-related hospitalizations (rate ratio = 0.43; P 
= 0.006) and cardioversions (rate ratio = 0.36; P = 0.0004) 
within the blanking period. The authors concluded that 
short-term oral amiodarone treatment following AF 
ablation did not significantly reduce AF recurrence at 6-
months, but it more than halved atrial arrhythmia related 
hospitalization and cardioversion rates during the blanking 
period (Darkner S et al, Eur Heart J 2014; 35: 3356-3364).  
 
ROCKET AF trial: Every Seventh Patient Had 
Significant Valvular Disease (SVD) Barring Mitral 
Stenosis & Prosthetic Valves / AF Patients With SVD 
Experienced the Same Stroke-Prevention Benefit from 
Oral Anticoagulants as did AF Patients Without SVD, 
but Bleeding Rates Were Higher With Rivaroxaban  
 In the ROCKET AF trial among 14 171 patients with 
non-valvular AF, defined as the presence of AF in the 
absence of mitral stenosis or prosthetic valves, 2003 
(14.1%) had significant valvular disease (SVD) (mitral 
regurgitation predominating at ~90%, followed by aortic 
regurgitation at 25%, and aortic stenosis at 11%, exceeding 
100% due to cases with more than one type of valvular 
lesion). Patients with SVD were older and had more 
comorbidities. The rate of stroke or systemic embolism 
with rivaroxaban vs. warfarin was consistent among 
patients with SVD [2 vs. 2.4%; hazard ratio - HR 0.83) and 
without SVD (1.96 vs. 2.22%; HR 0.89; P=NS). However, 
rates of major and non-major clinically relevant bleeding 
with rivaroxaban vs warfarin were higher in patients with 
SVD (20% rivaroxaban vs 17% warfarin; HR 1.25) vs 
those without (14% in both), even when controlling for risk 
factors and potential confounders. In intracranial 
hemorrhage, there was no interaction between patients 
with and without SVD where the overall rate was lower 
among those randomized to rivaroxaban. The authors 
concluded that many patients with ‘non-valvular atrial 
fibrillation’ have significant valve lesions. Their risk of 
stroke is similar to that of patients without SVD after 
controlling for stroke risk factors. Efficacy of rivaroxaban 
vs warfarin was similar in patients with and without SVD; 
however, the observed risk of bleeding was higher with 
rivaroxaban in patients with SVD but was the same among 
those without SVD (Breihardt G et al, Eur Heart J 2014; 
35: 3377-3385).  
 
ADVANCE-ON: In Type 2 Diabetes, Blood-Pressure 
Lowering but not Glucose Control Lowers Mortality or 
Macrovascular Events at 6 Years  
In the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled 
Evaluation (ADVANCE) trial, antihypertensive therapy 
with perindopril and indapamide reduced mortality in 
patients with type 2 diabetes, but intensive glucose control, 
(glycated hemoglobin <6.5%), did not. Among 8494 out of 
11,140 patients participating in the post-trial long-term (6-
year) follow-up, reductions in the risk of death or 
cardiovascular death were attenuated in the group 
receiving anti-hypertensive therapy but remained 
significant at the end of the post-trial follow-up (hazard 
ratios 0.91, P=0.03 and 0.88, P=0.04, respectively), while 
no differences were observed between the intensive-
glucose-control group and the standard-glucose-control 
group. The authors concluded that antihypertensive 
therapy in diabetics is effective in reducing mortality, an 
effect attenuated but still evident over 6 years, while  there 
is no evidence that intensive glucose control has any long-
term benefits (Zoungas S et al, N Engl J Med 2014; 
371:1392-1406).   
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DAPT Study: 30 Instead of 12 Months of Dual 
Antiplatelet Therapy After Drug-Eluting Stents 
Reduces Stent Thrombosis and MACCE but Increases 
Risk of Bleeding 
A total of 9961 patients receiving drug-eluting stents 
(DES) were randomized after 12 months to continue 
thienopyridine treatment or to receive placebo for another 
18 months. Continued treatment with thienopyridine, as 
compared with placebo, reduced stent thrombosis (0.4% vs 
1.4%; hazard ratio-HR, 0.29; P<0.001) and major adverse 
cardiovascular and cerebrovascular events (MACCE: 
death, myocardial infarction, or stroke) (4.3% vs 5.9%; 
HR, 0.71; P<0.001). The rate of bleeding was increased 
with continued thienopyridine treatment (2.5% vs 1.6%, 
P=0.001). Risk of stent thrombosis and myocardial 
infarction increased in both groups during the 3 months 
after discontinuation of thienopyridine treatment. The 
authors concluded that dual antiplatelet therapy beyond 1 
year after DES significantly reduced the risks of stent 
thrombosis and MACCE but was associated with an 
increased risk of bleeding (Mauri L et al, N Engl J Med 
2014; 371:2155-2166).   
 
ARCTIC-Interruption Trial: No Benefit from Dual-
Antiplatelet Treatment Beyond 1 Year After DES  
After 1 year of follow-up, 1259 patients having drug-
eluting stent (DES) implantation were randomized to 
interruption of dual antiplatelet therapy (DAPT) while 
maintaining aspirin (interruption group, n=624) or to 
DAPT continuation for 6–18 months (continuation group, 
n=635). After a median of 17 months, the primary endpoint 
(death, MI, stent thrombosis, stroke, or urgent revasculari-
sation) occurred in 27 (4%) patients in the interruption 
group and 24 (4%) patients in the continuation group 
(hazard ratio -HR 1.17; p=NS). Major bleeding occurred 
more often in the continuation group (n=7, 1% vs n=1, 
<0·5%; HR 0.15; p=0.073). Major or minor bleedings were 
also more common in the continuation group compared 
with the interruption group (n=12, 2% vs n=3, 1%; HR 
0.26; p=0.04). The authors concluded that extension of 
DAPT beyond 1 year after stenting with DES confers no 
apparent benefit but instead harm when no event has 
occurred within the first year after stenting. N.B.: high-risk 
patients were not randomized in this study (Collet J et al, 
Lancet 2014;384 (9954):1577–1585).  
 
DALLAS Heart Study: HDL Cholesterol Efflux 
Capacity, a Functional Property of HDL, was Inversely 
Associated With Incident Atherosclerotic 
Cardiovascular Disease in a Population-Based Cohort 
Free from Cardiovascular Disease at Baseline  
HDL cholesterol level, HDL particle concentration, and 
cholesterol efflux capacity were measured at baseline in 
2924 adults free from cardiovascular (CV) disease. Over a 
median follow-up of 9.4 years, cholesterol efflux capacity 
had minimal association with CV risk factors. Baseline 
HDL cholesterol level was not associated with CV events, 
whereas there was a 67% reduction in CV risk in the 
highest quartile of cholesterol efflux capacity vs the lowest 
quartile (hazard ratio, 0.33). Adding cholesterol efflux 
capacity to traditional risk factors was associated with 
better discrimination and reclassification indexes. The 
authors concluded that cholesterol efflux capacity, a new 
biomarker featuring a key step in reverse cholesterol 
transport, was inversely associated with the incidence of 
CV events in a population-based cohort. This association 
persisted after adjustment for traditional CV risk factors, 
HDL cholesterol level, and HDL particle concentration 
(Rohatgi A et al, N Engl J Med 2014;371:2383-93).  
 
Similar Survival of Bioprosthetic and Mechanical 
Aortic Valves in Patients Aged 50 to 69 Years  
Comparing survival and long-term outcome between 
bioprosthetic and mechanical valves in 4253 patients (aged 
50-69 years; propensity matching yielded 1001 patient 
pairs) who underwent aortic valve replacement (AVR) 
(1997-2004) over a median follow-up of 10.8 years, there 
were no differences in survival or stroke rates: actuarial 
15-year survival 60.6% vs 62.1%; 15-year cumulative 
incidence of stroke 7.7% vs 8.6%. The 15-year cumulative 
incidence of reoperation was higher in the bioprosthesis 
group (12.1% vs 6.9%; hazard ratio-HR, 0.52). The 15-
year cumulative incidence of major bleeding was higher in 
the mechanical prosthesis group (13.0% vs 6.6%; HR, 
1.75). The 30-day mortality rate was 18.7% after stroke, 
9.0% after reoperation, and 13.2% after major bleeding. 
The authors concluded that among propensity-matched 
patients (50-69 years) who had AVR with bioprosthetic 
compared with mechanical valves, there was no significant 
difference in 15-year survival or stroke. The bioprosthetic 
valve group had more reoperations but lower major 
bleeding. Thus, bioprosthetic valves may be a reasonable 
choice in patients aged 50 - 69 years (Chiang YP et al, 
JAMA 2014;312:1323-1329).   
 
Nonobstructive Coronary Artery Disease (CAD) 
Compared With no Apparent CAD, was Associated 
with a Significantly Greater 1-Year Risk of Myocardial 
Infarction (MI) and All-Cause Mortality 
Among 37 674 US veterans undergoing elective 
coronary angiography, 8384 (22%) had nonobstructive (≥1 
stenosis ≥20% but no stenosis ≥70%) CAD, and 20 899 
patients (55%) had obstructive (any stenosis ≥70% or left 
main -LM stenosis ≥50%) CAD. Within 1 year, 845 
patients died and 385 were rehospitalized for MI. Among 
patients with no apparent (no stenosis >20%) CAD, the 1-
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year MI rate was 0.11% (n = 8) and increased 
progressively by nonobstructive 1-vessel disease (1VD), 
0.24%; 2VD, 0.56%; 3VD, 0.59%; obstructive 1VD, 
1.18%; 2VD, 2.18%; and 3VD or LM, 2.47%. One-year 
MI rates increased with increasing CAD extent. Relative 
to those with no apparent CAD, patients with non-
obstructive 1VD had a hazard ratio (HR) for 1-year MI of 
2; 2VD HR, 4.6; 3VD HR, 4.5; obstructive 1VD HR, 9.0; 
2VD HR, 16.5; and 3VD or LM HR, 19.5. One-year 
mortality rates were associated with increasing CAD 
extent (1.38% in patients without apparent CAD to 4.30% 
in obstructive 3VD or LM). There was no significant 
association between nonobstructive 1VD or 2VD and 
mortality, but there were significant associations with 
mortality for nonobstructive 3VD (HR, 1.6), obstructive 
1VD (HR, 1.9), 2VD (HR, 2.8), and 3VD or LM (HR, 3.4). 
The authors concluded that among patients undergoing 
coronary angiography, nonobstructive CAD, compared 
with no apparent CAD, was associated with a greater 1-
year risk of MI and all-cause mortality (Maddox TM et al, 
JAMA 2014;312:1754-1763).  
 
CHARGE Consortium: Association of LDL 
Cholesterol–Related Genetic Variants With Aortic 
Valve Calcium and Incident Aortic Stenosis  
The prevalence of aortic valve calcium across the 
CHARGE cohorts (n=6942) was 32% (n = 2245). In the 
Malmö Diet and Cancer Study (MDCS) (n = 28 461), over 
a median follow-up of ~16 years, aortic stenosis (AS) 
developed in 17 per 1000 participants (n = 473) and aortic 
valve replacement for AS occurred in 7 per 1000 (n = 205). 
Plasma LDL-C, but not HDL-C or triglycerides (TG), was 
significantly associated with incident AS (hazard ratio -HR 
per mmol/L, 1.28; P =0.02; AS incidence: 1.3% and 2.4% 
in lowest and highest LDL-C quartiles, respectively). The 
LDL-C genetic risk scores (GRS), but not HDL-C or TG 
GRS, was associated with presence of aortic valve calcium 
in CHARGE (odds ratio - OR per GRS increment, 1.38; 
P =0.007) and with incident AS in MDCS (HR per GRS 
increment, 2.78; P = 0.02; AS incidence: 1.9% and 2.6% in 
lowest and highest GRS quartiles, respectively). The 
authors concluded that genetic predisposition to elevated 
LDL-cholesterol was associated with presence of aortic 
valve calcium and incidence of AS, supporting a causal 
association between LDL-C and aortic valve disease 
(Smith JG et al, JAMA. 2014;312:1764-1771). 
 
ISAR-CLOSURE Trial: in Trans-Femoral Coronary 
Angiography, Vascular Closure Devices were Non-
Inferior to Manual Compression Regarding Access-
Site Complications & Reduced Time to Hemostasis  
Of 4524 patients undergoing transfemoral coronary 
angiography (2011-2014), 3015 were randomly assigned 
to a vascular closure device (VCD) group (intravascular 
VCD in 1509, extravascular VCD in 1506) or manual 
compression group (n=1509). The primary end point 
(vascular complications at 30 days) was observed in 208 
patients (6.9%) in the VCD group and 119 patients (7.9%) 
in the manual compression group (noninferior). Time to 
hemostasis was shorter in patients with VCD (1 minute), 
vs manual compression (10 minutes) (P < 0.001). Time to 
hemostasis was shorter in patients with intravascular VCD 
(0.5 minute) vs extravascular VCD (2 minutes) (P <0.001) 
and closure device failure was also lower among those 
with intravascular vs extravascular VCD (80 patients - 
5.3%, vs 184 patients - 12.2%; P < 0.001). The authors 
concluded that in patients undergoing transfemoral 
coronary angiography, VCDs were noninferior to manual 
compression in terms of vascular access-site complications 
and reduced time to hemostasis (Schulz-Schüpke S et al, 
JAMA 2014;312:1981-1987).  
 
PROTECT AF: Percutaneous Left Atrial Appendage 
Closure at Least Noninferior to Warfarin for Atrial 
Fibrillation 3.8 Years of Follow-up  
Among 707 patients with nonvalvular AF and >1 stroke 
risk factor randomized to left atrial appendage closure 
(n = 463) or warfarin (n = 244; target INR 2-3), over a 
mean follow-up of 3.8 years, there were 39 events (8.4%) 
in the device group and 34 events among 244 patients 
(13.9%) in the warfarin group (rate ratio, 0.60), meeting 
prespecified criteria for both noninferiority and 
superiority. Patients in the device group hadd lower rates 
of both cardiovascular mortality (3.7% vs 9%; hazard ratio 
-HR, 0.40; P =0.005) and all-cause mortality (12.3% vs 
18.0%; HR, 0.66; P = 0.04). The authors concluded that 
after 3.8 years of follow-up among patients with 
nonvalvular AF at high risk for stroke, percutaneous LAA 
closure met criteria for both noninferiority and superiority, 
compared with warfarin, for preventing stroke, systemic 
embolism, and cardiovascular death, as well as superiority 
for cardiovascular and all-cause mortality (Reddy VY et 
al, JAMA 2014;312:1988-1998). 
 
 
HEAT PPCI Trial: Unfractionated Heparin Superior 
to Bivalirudin in Primary Percutaneous Coronary 
Intervention  
Among 1812 patients undergoing emergency 
angiography randomly assigned to bivalirudin (n=905) or 
heparin (n=907), 751 (83%) and 740 (82%), respectively, 
had primary percutaneous coronary intervention (PPCI). 
Rate of GP IIb/IIIa inhibitor use was similar in the 2 
groups. The primary efficacy outcome (all-cause 
mortality, cerebrovascular accident, reinfarction, or 
unplanned target lesion revascularisation) occurred in 79 
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(8.7%) patients in the bivalirudin group and 52 (5.7%) in 
the heparin group (absolute risk difference 3%; relative 
risk -RR 1.52, p=0.01). The primary safety outcome (major 
bleeding) occurred in 32 (3.5%) in the bivalirudin group 
and 28 (3.1%) in the heparin group (0.4%; RR 1.15, 
p=NS). The authors concluded that compared with 
bivalirudin, heparin reduces the incidence of major adverse 
ischemic events in the setting of PPCI, with no increase in 
bleeding. Systematic use of heparin rather than bivalirudin 
would significantly reduce drug costs (Shahzad A et al, 
Lancet 2014;384(9957):1849–1858).  
 
ACCORD Trial: Intensive Glycemic Control Reduces 
Risk of Ischemic Heart Disease  
Over ~5 years (mean 3.7 years of active treatment 
plus a further mean 1.2 years), among 10 251 adults aged 
40–79 years with type 2 diabetes and high mean glycated 
hemoglobin A1c (HbA1c) (8.3%), and risk factors for 
ischemic heart disease, assigned to intensive (target HbA1c 
<6%) or standard therapy (HbA1c 7–7.9%), myocardial 
infarction (MI) was less frequent in the intensive than in 
the standard therapy group during active treatment (hazard 
ratio -HR 0.80; p=0.015) and overall (HR 0.84; p=0.02). 
Findings were similar for combined MI, revascularisation, 
and unstable angina (active treatment HR 0.89, overall HR 
0.87) and for coronary revascularisation alone (HR 0.84) 
and unstable angina alone (HR 0.81) during full follow-up. 
The authors concluded that glycemia is a modifiable risk 
factor for ischemic heart disease in middle-aged diabetics 
and other cardiovascular risk factors (Gerstein HC et al, 
Lancet 2014; 384(9958):1936–1941).  
 
BIOSCIENCE: Ultrathin Strut Biodegradable 
Polymer Sirolimus-Eluting Stent Noninferior to 
Durable Polymer Everolimus-Eluting Stent  
A total of 2119 patients with 3139 lesions were 
randomly assigned to biodegradable polymer sirolimus-
eluting stents (SES) (1063 patients, 1594 lesions) or 
durable polymer everolimus-eluting stents (EES) (1056 
patients, 1545 lesions); 407 (19%) STEMI patients. Target 
lesion failure with biodegradable polymer SES (69 cases; 
6·5%) was non-inferior to durable polymer EES (70 cases; 
6.6%) at 1 year. No significant differences were noted in 
rates of definite stent thrombosis: 9 (0.9%) vs 4 (0.4%), 
rate ratio -RR 2.26, p=NS). Biodegradable polymer SES 
were associated with improved outcome compared with 
durable polymer EES in the subgroup of patients with 
STEMI: 7 (3.3%) vs 17 (8.7%) (RR 0.38, p=0.024, p for 
interaction=0.014). The authors concluded that 
biodegradable polymer SES were non-inferior to durable 
polymer EES for the combined safety and efficacy 
outcome target lesion failure at 12 months (Pilgrim T et al, 
Lancet 2014; 384 (9960):2111–2122).  
 
Individual-Patient Data Meta-Analysis of 10 
Randomized Trials: No Benefit of β-Blockers in 
Patients With Heart Failure Plus Atrial Fibrillation  
Individual-patient data from 10 randomized controlled 
trials (N= 18,254) of the comparison of β blockers vs 
placebo in heart failure, 13,946 (76%) having sinus rhythm 
and 3066 (17%) atrial fibrillation, showed crude death 
rates over a mean follow-up of 1.5 years of 16% in patients 
with sinus rhythm and 21% in patients with atrial 
fibrillation. β-blocker therapy led to a significant reduction 
in all-cause mortality in patients with sinus rhythm (hazard 
ratio-HR 0.73; p<0·001), but not in patients with atrial 
fibrillation (HR 0.97; p=NS). The authors concluded that 
β blockers should not be used preferentially over other 
rate-control medications and not regarded as standard 
therapy to improve prognosis in patients with concomitant 
heart failure and atrial fibrillation (Kotecha D et al, Lancet 
2014; 384(9961):2235–2243).  
 
Systematic Review and Meta-Analysis: Association of 
Atrial Fibrillation with Silent Cerebral Infarctions 
A total of 11 studies including 5317 patients with mean 
ages from 50 to 83.6 years reported on the association 
between atrial fibrillation (AF) and silent cerebral 
infarctions (SCIs). When computed tomography (CT) and 
magnetic resonance imaging (MRI) studies were 
combined, AF was associated with SCIs in patients with 
no history of symptomatic stroke (odds ratio, 2.62). This 
association was independent of AF type (paroxysmal vs 
persistent). The results were not altered significantly when 
the analysis was restricted to studies that met at least 70% 
of the maximum possible quality score (odds ratio, 3.06). 
Seventeen studies reported the prevalence of SCIs. The 
overall prevalence of SCI lesions on MRI and CT among 
patients with AF was 40% and 22%, respectively. The 
authors concluded that atrial fibrillation is associated with 
more than a 2-fold increase in the odds for silent cerebral 
infarction (Kalantarian S et al, Ann Intern Med 
2014;161:650-658).  
 
Danish Cohort Study: Risk for Serious Bleeding and 
Thromboembolism in Patients With Atrial Fibrillation 
(AF) Associated With use of Nonsteroidal Anti-
Inflammatory Drugs (NSAID) 
Of 150,900 patients with AF (median age, 75 years; 
47% female), 53,732 (35.6%) were prescribed an NSAID 
over 6.2 years. There were 17,187 (11%) occurrences of 
serious bleeding and 19,561 (13%) events of 
thromboembolism. At 3 months, the absolute risk for 
serious bleeding within 14 days of NSAID exposure was 
3.5 events per 1000 patients compared with 1.5 events per 
1000 patients without NSAID exposure. Use of NSAIDs 
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was associated with increased absolute risks for serious 
bleeding and thromboembolism across all antithrombotic 
regimens and NSAID types. The authors concluded that 
physicians should exercise caution with NSAIDs in 
patients with AF (Lamberts M et al, Ann Intern Med 
2014;161:690-698).  
 
A Cohort Study: Renin–Angiotensin System Blockade 
Therapy Prolongs Survival After Surgical Aortic Valve 
Replacement (SAVR) for Severe Aortic Stenosis  
Comparing 594 matched pairs among patients who 
were prescribed angiotensin-converting enzyme inhibitors 
or angiotensin-receptor blockers after SAVR for severe AS 
(1991-2010) (n=741) and those who did not receive these 
agents (n=1011), survival rates at 1, 5, and 10 years were 
significantly greater in the treated group than in the 
untreated group (99%, 90%, and 71% vs 96%, 78%, and 
49%, respectively; P < 0.001). The authors concluded that 
renin–angiotensin system blockade therapy is associated 
with increased survival rates in patients after SAVR for 
severe AS, dictating the need for a randomized trial to 
further confirm this finding (Goel SS et al, Ann Intern 
Med 2014;161:699-710).  
 
Meta-Analysis: Coronary Artery Bypass Grafting 
(CABG) is Preferred Over Percutaneous Coronary 
Intervention (PCI) in Diabetics, Albeit with Increased 
Risk of Stroke  
Meta-analysis of 40 randomized, controlled trials 
comparing PCI (with drug-eluting or bare-metal stents) 
with CABG in adults with diabetes with multivessel or left 
main coronary artery disease indicated that the primary 
outcome (a composite of all-cause mortality, nonfatal 
myocardial infarction, and stroke) increased with PCI 
(odds ratio -OR, 1.33). PCI resulted in increased mortality 
(OR, 1.44), no change in the number of myocardial 
infarctions (OR, 1.33), and fewer strokes (OR, 0.56). The 
authors concluded that CABG seems to be the preferred 
revascularization technique in diabetics, however, because 
of residual uncertainties and increased risk for stroke with 
CABG, clinical judgment is required (Tu B et al, Ann 
Intern Med 2014;161:724-732).  
 
Coronary Angiography and PCI via Radial vs Femoral 
Route on Uninterrupted Oral Anticoagulation with 
Warfarin: Fewer Bleeds with Radial Access in PCI 
Among 255 consecutive patients in whom warfarin was 
continued who underwent coronary angiography (INR 
>1.8), 97 also underwent percutaneous coronary 
intervention (PCI) (27% femoral vs 73% radial). No 
significant difference was seen in bleeds between femoral 
(2.8%) and radial (1.6%, P =NS) during coronary 
angiography alone. However, PCI via the femoral artery 
had more bleeding (19.2% vs 1.4%, P=0.005) and 
transfusions (15% vs 0%, P = 0.004) than via the radial 
artery. Patients who underwent PCI using radial access 
were less likely to have any vascular or bleeding 
complications (1% vs 23%, P = 0.001) (Baker NC et al, 
Am Heart J 2014; 168:537–544).  
 
Important Review and Other Articles  
 
Scientific statement from AHA/ACC against the use of 
ECG as a screening tool for sudden death in the young, but 
in favor of widespread dissemination of automatic external 
defibrillators in the athletic field and elsewhere (Maron BJ 
et al, J Am Coll Cardiol 2014;64:1479-1514), Expert 
consensus document (SCAI/AATS/ACC/STS) for 
transcatheter mitral valve repair (Tommaso CL et al, J Am 
Coll Cardiol 2014;64:1515-1526), Thoracic aortic 
aneurysm (Goldfinger JZ et al, J Am Coll Cardiol 
2014;64:1725-1739), Left ventricular non-compaction 
(Arbustini E et al, J Am Coll Cardiol 2014;64:1840-1850), 
2014 ACC/AHA/AATS/ PCNA/SCAI/STS Guideline 
Update for diagnosis and management of patients with 
stable ischemic heart disease (Fihn HD et al, J Am Coll 
Cardiol 2014;64:1929-1949), 2014 AHA/ACC/HRS 
Guideline for the management of patients with atrial 
fibrillation (January CT et al, J Am Coll Cardiol 
2014;64:2246-2280), Vaccine for atherosclerosis (Shah 
PK et al, J Am Coll Cardiol 2014;64:2779-2791), Post-
thrombotic syndrome (Kahn SR et al, Circulation 
2014;130:1636-1661), Transcatheter therapy of mitral 
regurgitation (Herrmann HC & Maisano F, Circulation 
2014;130:1712-1722), Pulmonary hypertension (Rich JD 
& Rich S, Circulation 2014;130:1820-1830), Rheumatic 
fever (Essop MR & Peters F, Circulation 2014, 130:2181-
2188), 2014 ESC Guidelines on pulmonary embolism 
(Konstantinides S, et al, Eur Heart J 2014; 35: 3033-3073), 
Management of antithrombotic therapy in AF patients 
presenting with ACS and/or undergoing PCI or valve 
interventions (Lip G et al, Eur Heart J 2014 35: 3155-
3179), Acute pericarditis (LeWinter MM, N Engl J Med 
2014;371:2410-2416), TAVI (Horne A et al, Am Hear J 
2014;168:414-423),   
 
Just-in (8/1/2015): the U.S. FDA approved Daiichi 
Sankyo’s new oral anticoagulant drug, edoxaban 
(Savaysa) for patients with non-valvular atrial fibrillation, 
and patients with deep vein thrombosis and/or pulmonary 
embolism. 
 
9/1/2015: Portola Pharmaceuticals Inc announced that 
its experimental drug, andexanet alfa, met the main goal 
of reversing the effect of rivaroxaban (Xarelto) and 
apixaban (Eliquis).  
 
